Fluticasone furoate

From WikiProjectMed
Jump to navigation Jump to search

Fluticasone furoate
Fluticasone furoate.svg
Clinical data
License data
Routes of
Intranasal, oral inhalation
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetic data
Bioavailability0.51% (Intranasal)
Protein binding91%
Hepatic (CYP3A4-mediated)
Elimination half-life15 hours
  • (6α,11β,16α,17α)-6,9-difluoro-17-{[(fluoro-methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.158.130 Edit this at Wikidata
Chemical and physical data
Molar mass538.58 g·mol−1
3D model (JSmol)
  • CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)OC(=O)C5=CC=CO5)C)O)F)C)F
  • InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1

Fluticasone furoate is a corticosteroid for the treatment of non-allergic and allergic rhinitis administered by a nasal spray.[2] It is also available as an inhaled corticosteroid to help prevent and control symptoms of asthma. It is derived from cortisol.[3] Unlike fluticasone propionate, which is only approved for children four years and older, fluticasone furoate is approved in children as young as two years of age when used for allergies.[4][5]

It was approved for medical use in the United States in April 2007, and in the European Union in November 2008.[6][7]

Society and culture

Brand names

In the US it is marketed by GlaxoSmithKline for asthma as Arnuity Ellipta and is only available with a prescription.[8] It is marketed over-the-counter for allergic rhinitis as Flonase Sensimist.[9] The Veramyst brand name has been discontinued in the U.S.[4] It is also marketed as Allermist (Japan, アラミスト) and Avamys (Australia, Canada, EU, South Africa, South America, Mexico, Israel, Italy, India and South Korea).

The combination drug fluticasone furoate/vilanterol, marketed as Breo Ellipta (US, Canada, New Zealand) and Relvar Ellipta (EU, UK),[10][11][12] is approved for use in the United States for long-term maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD).[10] It is also approved for the treatment of asthma.[10]

See also


  1. ^ a b "Fluticasone Use During Pregnancy". Drugs.com. 9 January 2019. Retrieved 4 February 2020.
  2. ^ Bruni FM, De Luca G, Venturoli V, Boner AL (2009). "Intranasal corticosteroids and adrenal suppression". Neuroimmunomodulation. 16 (5): 353–62. doi:10.1159/000216193. PMID 19571596. S2CID 35006163.
  3. ^ Kaliner, Michael A. (2011). Rhinitis, An Issue of Immunology and Allergy Clinics - E-Book. Elsevier Health Sciences. ISBN 9781455709328.
  4. ^ a b "Veramyst". Drugs.com. 21 June 2019. Retrieved 4 February 2020.
  5. ^ "Veramyst- fluticasone furoate spray, metered". DailyMed. 1 March 2010. Retrieved 4 February 2020.
  6. ^ "Drug Approval Package: Veramyst (fluticasone furoate) NDA #022051". U.S. Food and Drug Administration (FDA). 30 August 2010. Retrieved 4 February 2020.
  7. ^ "Avamys EPAR". European Medicines Agency (EMA). Retrieved 5 June 2020.
  8. ^ "Arnuity Ellipta- fluticasone furoate powder". DailyMed. 26 June 2019. Retrieved 4 February 2020.
  9. ^ "Flonase Sensimist Allergy Relief- fluticasone furoate spray, metered". DailyMed. 30 May 2019. Retrieved 4 February 2020.
  10. ^ a b c "Breo Ellipta- fluticasone furoate and vilanterol trifenatate powder". DailyMed. 7 January 2019. Retrieved 4 February 2020.
  11. ^ "Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed - Summary of Product Characteristics (SmPC)". (emc). 3 January 2019. Retrieved 4 February 2020.
  12. ^ "Relvar Ellipta EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 4 February 2020.

External links